Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
Abstract Objective The aim of this meta‐analysis was to summarize the available results of immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based information for their potential predictive value of efficacy. Methods We searched PubMed, EMBASE, Web of Science, The Co...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5800 |
| _version_ | 1827932370985025536 |
|---|---|
| author | Lin‐Lu Li Cheng‐Feng Yu Hong‐Ting Xie Zheng Chen Bo‐Hui Jia Fei‐Yu Xie Ya‐Fang Cai Peng Xue Shi‐Jie Zhu |
| author_facet | Lin‐Lu Li Cheng‐Feng Yu Hong‐Ting Xie Zheng Chen Bo‐Hui Jia Fei‐Yu Xie Ya‐Fang Cai Peng Xue Shi‐Jie Zhu |
| author_sort | Lin‐Lu Li |
| collection | DOAJ |
| description | Abstract Objective The aim of this meta‐analysis was to summarize the available results of immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based information for their potential predictive value of efficacy. Methods We searched PubMed, EMBASE, Web of Science, The Cochrane Library, and ClinicalTrials (from January 1, 1975 to November 1, 2021). The hazard ratios (HR) and its 95% confidence intervals (CIs) and tumor response rate of the included studies were extracted. Results Eleven studies were eventually included and the pooled results showed that programmed cell death ligand 1 (PD‐L1) positive: objective response rate (ORR) (relative risk [RR] = 1.39, 95% CI [0.48, 4.03], p = 0.54), with high heterogeneity (p = 0.05, I2 = 56%); disease control rate [DCR] (RR = 1.31, 95% CI [0.04, 38.57], p = 0.88), with high heterogeneity (p = 0.04, I2 = 75%); overall survival (OS) (HR = 0.89, 95% CI [0.74, 1.07], p = 0.22); and progression‐free survival (PFS) (HR = 0.83, 95% CI [0.59, 1.16], p = 0.27), with high heterogeneity (p = 0.005, I2 = 73.1%). TMB‐High (TMB‐H): OS (HR = 0.86, 95% CI [0.74, 1.00], p = 0.05); PFS (HR = 0.71, 95% CI [0.6, 0.85], p < 0.001). Lactate dehydrogenase (LDH) >upper limit of normal (ULN): OS (HR = 0.95, 95% CI [0.81, 1.11], p = 0.511). Asian patients: OS (HR = 0.87, 95% CI [0.72, 1.04], p = 0.135); White/Non‐Asian patients: OS (HR = 0.83, 95% CI [0.76, 0.90], p < 0.001). Liver metastasis patients: OS (HR = 0.93, 95% CI [0.83, 1.05], p = 0.229); PFS (HR = 0.84, 95% CI [0.67, 1.06], p = 0.141). Central nervous system (CNS) metastasis patients: OS (HR = 0.91, 95% CI [0.71, 1.17], p = 0.474); PFS (HR = 1.03, 95% CI [0.66, 1.60], p = 0.903). Conclusion The available research results do not support the recommendation of PD‐L1 positive and TMB‐H as predictors for the application of immune checkpoint inhibitors (ICIs) in SCLC patients. LDH, baseline liver metastasis and CNS metastasis may be used as markers/influencing factors for predicting the efficacy of ICIs in SCLC patients. Non‐Asian SCLC patients had better efficacy with ICIs in our results. |
| first_indexed | 2024-03-13T07:07:43Z |
| format | Article |
| id | doaj.art-82462ab784dc4d5394f75e26b3ead92c |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-13T07:07:43Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-82462ab784dc4d5394f75e26b3ead92c2023-06-06T07:30:47ZengWileyCancer Medicine2045-76342023-05-011210112111123310.1002/cam4.5800Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysisLin‐Lu Li0Cheng‐Feng Yu1Hong‐Ting Xie2Zheng Chen3Bo‐Hui Jia4Fei‐Yu Xie5Ya‐Fang Cai6Peng Xue7Shi‐Jie Zhu8Department of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaBeijing Sihui West District Hospital 100082 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaDepartment of Oncology Wangjing Hospital, China Academy of Chinese Medical Sciences 100102 Beijing ChinaAbstract Objective The aim of this meta‐analysis was to summarize the available results of immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based information for their potential predictive value of efficacy. Methods We searched PubMed, EMBASE, Web of Science, The Cochrane Library, and ClinicalTrials (from January 1, 1975 to November 1, 2021). The hazard ratios (HR) and its 95% confidence intervals (CIs) and tumor response rate of the included studies were extracted. Results Eleven studies were eventually included and the pooled results showed that programmed cell death ligand 1 (PD‐L1) positive: objective response rate (ORR) (relative risk [RR] = 1.39, 95% CI [0.48, 4.03], p = 0.54), with high heterogeneity (p = 0.05, I2 = 56%); disease control rate [DCR] (RR = 1.31, 95% CI [0.04, 38.57], p = 0.88), with high heterogeneity (p = 0.04, I2 = 75%); overall survival (OS) (HR = 0.89, 95% CI [0.74, 1.07], p = 0.22); and progression‐free survival (PFS) (HR = 0.83, 95% CI [0.59, 1.16], p = 0.27), with high heterogeneity (p = 0.005, I2 = 73.1%). TMB‐High (TMB‐H): OS (HR = 0.86, 95% CI [0.74, 1.00], p = 0.05); PFS (HR = 0.71, 95% CI [0.6, 0.85], p < 0.001). Lactate dehydrogenase (LDH) >upper limit of normal (ULN): OS (HR = 0.95, 95% CI [0.81, 1.11], p = 0.511). Asian patients: OS (HR = 0.87, 95% CI [0.72, 1.04], p = 0.135); White/Non‐Asian patients: OS (HR = 0.83, 95% CI [0.76, 0.90], p < 0.001). Liver metastasis patients: OS (HR = 0.93, 95% CI [0.83, 1.05], p = 0.229); PFS (HR = 0.84, 95% CI [0.67, 1.06], p = 0.141). Central nervous system (CNS) metastasis patients: OS (HR = 0.91, 95% CI [0.71, 1.17], p = 0.474); PFS (HR = 1.03, 95% CI [0.66, 1.60], p = 0.903). Conclusion The available research results do not support the recommendation of PD‐L1 positive and TMB‐H as predictors for the application of immune checkpoint inhibitors (ICIs) in SCLC patients. LDH, baseline liver metastasis and CNS metastasis may be used as markers/influencing factors for predicting the efficacy of ICIs in SCLC patients. Non‐Asian SCLC patients had better efficacy with ICIs in our results.https://doi.org/10.1002/cam4.5800biomarkersimmune checkpoint inhibitorsmeta‐analysissmall cell lung cancer |
| spellingShingle | Lin‐Lu Li Cheng‐Feng Yu Hong‐Ting Xie Zheng Chen Bo‐Hui Jia Fei‐Yu Xie Ya‐Fang Cai Peng Xue Shi‐Jie Zhu Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis Cancer Medicine biomarkers immune checkpoint inhibitors meta‐analysis small cell lung cancer |
| title | Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis |
| title_full | Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis |
| title_fullStr | Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis |
| title_full_unstemmed | Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis |
| title_short | Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis |
| title_sort | biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors a meta analysis |
| topic | biomarkers immune checkpoint inhibitors meta‐analysis small cell lung cancer |
| url | https://doi.org/10.1002/cam4.5800 |
| work_keys_str_mv | AT linluli biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT chengfengyu biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT hongtingxie biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT zhengchen biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT bohuijia biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT feiyuxie biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT yafangcai biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT pengxue biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis AT shijiezhu biomarkersandfactorsinsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitorsametaanalysis |